nach oben

Basic Research in Cardiology

Erschienen in:

01.09.2015 | Invited Editorial

Hydrogen sulfide and PKG in ischemia–reperfusion injury: sources, signaling, accelerators and brakes

verfasst von: Ioanna Andreadou, Efstathios K. Iliodromitis, Csaba Szabo, Andreas Papapetropoulos

Erschienen in: Basic Research in Cardiology | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

Over the past decade, hydrogen sulfide has emerged as an important cardioprotective molecule with potential for clinical applications. Although several pathways have been proposed to mediate the beneficial effects of H₂S, the NO/cGMP axis has attracted significant attention. Recent evidence has suggested that cGMP-dependent protein kinase can lie both downstream and upstream of H₂S. The current literature on this topic is reviewed and data from recent studies are integrated to propose a unifying model.

Abe K, Kimura H (1996) The possible role of hydrogen sulfide as an endogenous neuromodulator. J Neurosci 16:1066–1071PubMed

Altaany Z, Ju Y, Yang G, Wang R (2014) The coordination of S-sulfhydration, S-nitrosylation, and phosphorylation of endothelial nitric oxide synthase by hydrogen sulfide. Sci Signal 7:ra87. doi:10.1126/scisignal.2005478 PubMedCrossRef

Andreadou I, Iliodromitis EK, Rassaf T, Schulz R, Papapetropoulos A, Ferdinandy P (2015) The role of gasotransmitters NO, H₂S, CO in myocardial ischemia/reperfusion injury and cardioprotection by preconditioning, postconditioning, and remote conditioning. Br J Pharmacol 172:1587–1606. doi:10.1111/bph.12811 PubMedCrossRef

Bian JS, Yong QC, Pan TT, Feng ZN, Ali MY, Zhou S, Moore PK (2006) Role of hydrogen sulfide in the cardioprotection caused by ischemic preconditioning in the rat heart and cardiac myocytes. J Pharmacol Exp Ther 316:670–678. doi:10.1124/jpet.105.092023 PubMedCrossRef

Bibli SI, Andreadou I, Chatzianastasiou A, Tzimas C, Sanoudou D, Kranias E, Brouckaert P, Coletta C, Szabo C, Kremastinos DT, Iliodromitis EK, Papapetropoulos A (2015) Cardioprotection by H₂S engages a cGMP-dependent protein kinase G/phospholamban pathway. Cardiovasc Res 106:432–442. doi:10.1093/cvr/cvv129 PubMedCrossRef

Bucci M, Papapetropoulos A, Vellecco V, Zhou Z, Pyriochou A, Roussos C, Roviezzo F, Brancaleone V, Girino G (2010) Hydrogen sulfide is an endogenous inhibitor of phosphodiesterase activity. Arterioscler Thromb Vasc Biol 30:1998–2004. doi:10.1161/ATVBAHA.110.209783 PubMedCrossRef

Bucci M, Papapetropoulos A, Vellecco V, Zhou Z, Zaid A, Giannogonas P, Cantalupo A, Dhayade S, Karalis KP, Wang W, Feil R, Cirino G (2012) cGMP-dependent protein kinase contributes to hydrogen sulfide-stimulated vasorelaxation. PLoS One 7:e53319. doi:10.1371/journal.pone.0053319 PubMedCentralPubMedCrossRef

Bucci M, Vellecco V, Cantalupo A, Brancaleone V, Zhou Z, Evangelista S, Calderone V, Papapetropoulos A, Cirino G (2014) Hydrogen sulfide accounts for the peripheral vascular effects of zofenopril independently of ACE inhibition. Cardiovasc Res 102:138–147. doi:10.1093/cvr/cvu026 PubMedCrossRef

Burley DS, Ferdinandy P, Baxter GF (2007) Cyclic GMP and protein kinase-G in myocardial ischaemia-reperfusion: opportunities and obstacles for survival signaling. Br J Pharmacol 152:855–869. doi:10.1038/sj.bjp.0707409 PubMedCentralPubMedCrossRef

10.

Burley DS, Cox CD, Zhang J, Wann KT, Baxter GF (2014) Natriuretic peptides modulate ATP-sensitive K(+) channels in rat ventricular cardiomyocytes. Basic Res Cardiol 109:402–416. doi:10.1007/s00395-014-0402-4 PubMedCentralPubMedCrossRef

11.

Calvert JW, Jha S, Gundewar S, Elrod JW, Ramachandran A, Pattillo CB, Kevil CG, Lefer DJ (2009) Hydrogen sulfide mediates cardioprotection through Nrf2 signaling. Circ Res 105:365–374. doi:10.1161/CIRCRESAHA.109.199919 PubMedCentralPubMedCrossRef

12.

Calvert JW, Elston M, Nicholson CK, Gundewar S, Jha S, Elrod JW, Ramachandran A, Lefer DJ (2010) Genetic and pharmacologic hydrogen sulfide therapy attenuates ischemia-induced heart failure in mice. Circulation 122:11–19. doi:10.1161/CIRCULATIONAHA.109.920991 PubMedCentralPubMedCrossRef

13.

Chouchani ET, Methner C, Nadtochiy SM, Logan A, Pell VR, Ding S, James AM, Cochemé HM, Reinhold J, Lilley KS, Partridge L, Fearnley IM, Robinson AJ, Hartley RC, Smith RA, Krieg T, Brookes PS, Murphy MP (2013) Cardioprotection by S-nitrosation of a cysteine switch on mitochondrial complex I. Nat Med 19:753–759. doi:10.1038/nm.3212 PubMedCentralPubMedCrossRef

14.

Cohen MV, Yang XM, Liu Y, Solenkova NV, Downey JM (2010) Cardioprotective PKG-independent NO signaling at reperfusion. Am J Physiol Heart Circ Physiol 299:H2028–H2036. doi:10.1152/ajpheart.00527.2010 PubMedCentralPubMedCrossRef

15.

Coletta C, Papapetropoulos A, Erdelyi K, Olah G, Módis K, Panopoulos P, Asimakopoulou A, Gerö D, Sharina I, Martin E, Szabo C (2012) Hydrogen sulfide and nitric oxide are mutually dependent in the regulation of angiogenesis and endothelium-dependent vasorelaxation. Proc Natl Acad Sci USA 109:9161–9166. doi:10.1073/pnas.1202916109 PubMedCentralPubMedCrossRef

16.

Das A, Samidurai A, Hoke NN, Kukreja RC, Salloum FN (2015) Hydrogen sulfide mediates the cardioprotective effects of gene therapy with PKG-Iα. Basic Res Cardiol 110:42–53. doi:10.1007/s00395-015-0500-y PubMedCrossRef

17.

Elrod JW, Calvert JW, Morrison J, Doeller JE, Kraus DW, Tao L, Jiao X, Scalia R, Kiss L, Szabo C, Kimura H, Chow CW, Lefer DJ (2007) Hydrogen sulfide attenuates myocardial ischemia–reperfusion injury by preservation of mitochondrial function. Proc Natl Acad Sci USA 104:15560–15565. doi:10.1073/pnas.0705891104 PubMedCentralPubMedCrossRef

18.

Fraccarollo D, Galuppo P, Motschenbacher S, Ruetten H, Schäfer A, Bauersachs J (2014) Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction: cardioprotection over ACE inhibition. Basic Res Cardiol 109:421. doi:10.1007/s00395-014-0421-1 PubMedCrossRef

19.

Garcia-Dorado D, Agulló L, Sartorio CL, Ruiz-Meana M (2009) Myocardial protection against reperfusion injury: the cGMP pathway. Thromb Haemost 101:635–642. doi:10.1160/TH08-11-0764 PubMed

20.

Greiner R, Pálinkás Z, Bäsell K, Becher D, Antelmann H, Nagy P, Dick TP (2013) Polysulfides link H₂S to protein thiol oxidation. Antioxid Redox Signal 19:1749–1765. doi:10.1089/ars.2012.5041 PubMedCentralPubMedCrossRef

21.

Heusch G (2015) Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-, and remote conditioning. Circ Res 116:674–699. doi:10.1161/CIRCRESAHA.116.305348 PubMedCrossRef

22.

Hosoki R, Matsuki N, Kimura H (1997) The possible role of hydrogen sulfide as an endogenous smooth muscle relaxant in synergy with nitric oxide. Biochem Biophys Res Commun 237:527–531. doi:10.1006/bbrc.1997.6878 PubMedCrossRef

23.

Inserte J, Barba I, Poncelas-Nozal M, Hernando V, Agullo L, Ruiz-Meana M, Garcia-Dorado D (2011) cGMP/PKG pathway mediates myocardial postconditioning protection in rat hearts by delaying normalization of intracellular acidosis during reperfusion. J Mol Cell Cardiol 50:903–909. doi:10.1016/j.yjmcc.2011.02.013 PubMedCrossRef

24.

Inserte J, Hernando V, Ruiz-Meana M, Poncelas-Nozal M, Fernandez C, Agullo L, Sartorio C, Vilardosa U, Garcia-Dorado D (2014) Delayed phospholamban phosphorylation in post-conditioned heart favours Ca²⁺ normalization and contributes to protection. Cardiovasc Res 103:542–553. doi:10.1093/cvr/cvu163 PubMedCrossRef

25.

Ishii I, Akahoshi N, Yu XN, Kobayashi Y, Namekata K, Komaki G, Kimura H (2004) Murine cystathionine gamma-lyase: complete cDNA and genomic sequences, promoter activity, tissue distribution and developmental expression. Biochem J 381:113–123. doi:10.1042/BJ20040243 PubMedCentralPubMedCrossRef

26.

Johansen D, Ytrehus K, Baxter GF (2006) Exogenous hydrogen sulfide (H₂S) protects against regional myocardial ischemia-reperfusion injury—Evidence for a role of K ATP channels. Basic Res Cardiol 101:53–60. doi:10.1007/s00395-005-0569-9 PubMedCrossRef

27.

Kabil O, Banerjee R (2014) Enzymology of H₂S biogenesis, decay and signaling. Antioxid Redox Signal 20:770–782. doi:10.1089/ars.2013.5339 PubMedCentralPubMedCrossRef

28.

King AL, Polhemus DJ, Bhushan S, Otsuka H, Kondo K, Nicholson CK, Bradley JM, Islam KN, Calvert JW, Tao YX, Dugas TR, Kelley EE, Elrod JW, Huang PL, Wang R, Lefer DJ (2014) Hydrogen sulfide cytoprotective signaling is endothelial nitric oxide synthase nitric oxide dependent. Proc Natl Acad Sci USA 111:3182–3187. doi:10.1073/pnas.1321871111 PubMedCentralPubMedCrossRef

29.

Kondo K, Bhushan S, King AL, Prabhu SD, Hamid T, Koenig S, Murohara T, Predmore BL, Gojon G Jr, Gojon G Sr, Wang R, Karusula N, Nicholson CK, Calvert JW, Lefer DJ (2013) H₂S protects against pressure overload-induced heart failure via upregulation of endothelial nitric oxide synthase. Circulation 127:1116–1127. doi:10.1161/CIRCULATIONAHA.112.000855 PubMedCentralPubMedCrossRef

30.

Kranias EG, Hajjar RJ (2012) Modulation of cardiac contractility by the phospholamban/SERCA2a regulatome. Circ Res 110:1646–1660. doi:10.1161/CIRCRESAHA.111.259754 PubMedCentralPubMedCrossRef

31.

Methner C, Lukowski R, Grube K, Loga F, Smith RA, Murphy MP, Hofmann F, Krieg T (2013) Protection through postconditioning or a mitochondria-targeted S-nitrosothiol is unaffected by cardiomyocyte-selective ablation of protein kinase G. Basic Res Cardiol 108:337. doi:10.1007/s00395-013-0337-1 PubMedCrossRef

32.

Minamishima S, Kida K, Tokuda K, Wang H, Sips PY, Kosugi S, Mandeville JB, Buys ES, Brouckaert P, Liu PK, Liu CH, Bloch KD, Ichinose F (2011) Inhaled nitric oxide improves outcomes after successful cardiopulmonary resuscitation in mice. Circulation 124:1645–1653. doi:10.1161/CIRCULATIONAHA.111.025395 PubMedCentralPubMedCrossRef

33.

Módis K, Panopoulos P, Coletta C, Papapetropoulos A, Szabo C (2013) Hydrogen sulfide-mediated stimulation of mitochondrial electron transport involves inhibition of the mitochondrial phosphodiesterase 2A, elevation of cAMP and activation of protein kinase A. Biochem Pharmacol 86:1311–1319. doi:10.1016/j.bcp.2013.08.064 PubMedCrossRef

34.

Olson KR, Donald JA, Dombkowski RA, Perry SF (2012) Evolutionary and comparative aspects of nitric oxide, carbon monoxide and hydrogen sulfide. Respir Physiol Neurobiol 184:117–129. doi:10.1016/j.resp.2012.04.004 PubMedCrossRef

35.

Panopoulos P, Yang G, Asimakopoulou A, Topouzis S, Wang R, Szabo C, Papapetropoulos A (2015) Selectivity of hydrogen sulfide towards cyclic nucleotide phosphodiesterases. Nitric Oxide 47:S39. doi:10.1016/j.niox.2015.02.095 (abstract) CrossRef

36.

Papapetropoulos A, Pyriochou A, Altaany Z, Yang G, Marazioti A, Zhou Z, Jeschke MG, Branski LK, Herndon DN, Wang R, Szabó C (2009) Hydrogen sulfide is an endogenous stimulator of angiogenesis. Proc Natl Acad Sci USA 106:21972–21977. doi:10.1073/pnas.0908047106 PubMedCentralPubMedCrossRef

37.

Papapetropoulos A, Whiteman M, Cirino G (2015) Pharmacological tools for hydrogen sulphide research: a brief, introductory guide for beginners. Br J Pharmacol 172:1633–1637. doi:10.1111/bph.12806 PubMedCrossRef

38.

Polhemus DJ, Kondo K, Bhushan S, Bir SC, Kevil CG, Murohara T, Lefer DJ, Calvert JW (2013) Hydrogen sulfide attenuates cardiac dysfunction after heart failure via induction of angiogenesis. Circ Heart Fail 6:1077–1086. doi:10.1161/CIRCHEARTFAILURE.113.000299 PubMedCrossRef

39.

Polhemus DJ, Lefer DJ (2014) Emergence of hydrogen sulfide as an endogenous gaseous signaling molecule in cardiovascular disease. Circ Res 114:730–737. doi:10.1161/CIRCRESAHA.114.300505 PubMedCentralPubMedCrossRef

40.

Predmore BL, Lefer DJ (2011) Hydrogen sulfide-mediated myocardial pre- and postconditioning. Expert Rev Clin Pharmacol 4:83–96. doi:10.1586/ecp.10.56 PubMedCentralPubMedCrossRef

41.

Predmore BL, Kondo K, Bhushan S, Zlatopolsky MA, King AL, Aragon JP, Grinsfelder DB, Condit ME, Lefer DJ (2012) The polysulfide diallyl trisulfide protects the ischemic myocardium by preservation of endogenous hydrogen sulfide and increasing nitric oxide bioavailability. Am J Physiol Heart Circ Physiol 302:H2410–H2418. doi:10.1152/ajpheart.00044.2012 PubMedCentralPubMedCrossRef

42.

Salloum FN, Chau VQ, Hoke NN, Abbate A, Varma A, Ockaili RA, Toldo S, Kukreja RC (2009) Phosphodiesterase-5 inhibitor, tadalafil, protects against myocardial ischemia/reperfusion through protein-kinase G dependent generation of hydrogen sulfide. Circulation 120:S31–S36. doi:10.1161/CIRCULATIONAHA.108.843979 PubMedCentralPubMedCrossRef

43.

Salloum FN, Das A, Samidurai A, Hoke NN, Chau VQ, Ockaili RA, Stasch JP, Kukreja RC (2012) Cinaciguat, a novel activator of soluble guanylate cyclase, protects against ischemia/reperfusion injury: role of hydrogen sulfide. Am J Physiol Heart Circ Physiol 302:H1347–H1354. doi:10.1152/ajpheart.00544.2011 PubMedCentralPubMedCrossRef

44.

Sen N, Paul BD, Gadalla MM, Mustafa AK, Sen T, Xu R, Kim S, Snyder SH (2012) Hydrogen sulfide-linked sulfhydration of NF-κB mediates its antiapoptotic actions. Mol Cell 45:13–24. doi:10.1016/j.molcel.2011.10.021 PubMedCentralPubMedCrossRef

45.

Sivarajah A, Collino M, Yasin M, Benetti E, Gallicchio M, Mazzon E, Cuzzocrea S, Fantozzi R, Thiemermann C (2009) Anti-apoptotic and anti-inflammatory effects of hydrogen sulfide in a rat model of regional myocardial I/R. Shock 31:267–274. doi:10.1097/SHK.0b013e318180ff89 PubMedCrossRef

46.

Stubbert D, Prysyazhna O, Rudyk O, Scotcher J, Burgoyne JR, Eaton P (2014) Protein kinase G Ialpha oxidation paradoxically underlies blood pressure lowering by the reductant hydrogen sulfide. Hypertension 64:1344–13451. doi:10.1161/HYPERTENSIONAHA.114.04281 PubMedCrossRef

47.

Szabó G, Veres G, Radovits T, Gero D, Módis K, Miesel-Gröschel C, Horkay F, Karck M, Szabó C (2011) Cardioprotective effects of hydrogen sulfide. Nitric Oxide 25:201–210. doi:10.1016/j.niox.2010.11.001 PubMedCentralPubMedCrossRef

48.

Tsai CY, Wen S-Y, Shibu MA, Yang Y-C, Peng H, Wang B, Wei Y-M, Chang H-Y, Lee C-Y, Huang C-Y, Kuo W-W (2015) Diallyl trisulfide protects against high glucose-induced cardiac apoptosis by stimulating the production of cystathionine gamma-lyase-derived hydrogen sulfide. Int J Cardiol 195:300–310. doi:10.1016/j.ijcard.2015.05.111 PubMedCrossRef

49.

Wallace JL, Wang R (2015) Hydrogen sulfide-based therapeutics: exploiting a unique but ubiquitous gasotransmitter. Nat Rev Drug Discov 14:329–345. doi:10.1038/nrd4433 PubMedCrossRef

50.

Wang R (2012) Physiological implications of hydrogen sulfide: a whiff exploration that blossomed. Physiol Rev 92:791–896. doi:10.1152/physrev.00017.2011 PubMedCrossRef

51.

Yuan G, Vasavda C, Peng Y-J, Makarenko VV, Raghuraman G, Nanduri J, Gadalla MM, Semenza GL, Kumar GK, Snyder SH, Prabhakar NR (2015) Protein kinase G regulated production of H₂S governs oxygen sensing. Sci Signal 8:ra37. doi:10.1126/scisignal.2005846 PubMedCentralPubMedCrossRef

52.

Zhou Z, Sharina I, Bucci M, Cirino G, Martin E, Papapetropoulos A (2015) Hydrogen sulfide regulates the redox status of soluble guanylyl cyclase. Nitric Oxide 47:S34. doi:10.1016/j.niox.2015.02.082 (abstract) CrossRef

Titel: Hydrogen sulfide and PKG in ischemia–reperfusion injury: sources, signaling, accelerators and brakes
verfasst von: Ioanna Andreadou
Efstathios K. Iliodromitis
Csaba Szabo
Andreas Papapetropoulos
Publikationsdatum: 01.09.2015
Verlag: Springer Berlin Heidelberg
Erschienen in: Basic Research in Cardiology / Ausgabe 5/2015
Print ISSN: 0300-8428
Elektronische ISSN: 1435-1803
DOI: https://doi.org/10.1007/s00395-015-0510-9

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2015

Cardiac microRNA-133 is down-regulated in thyroid hormone-mediated cardiac hypertrophy partially via Type 1 Angiotensin II receptor

NOS1 induces NADPH oxidases and impairs contraction kinetics in aged murine ventricular myocytes

Septic cardiomyopathy in rat LPS-induced endotoxemia: relative contribution of cellular diastolic Ca2+ removal pathways, myofibrillar biomechanics properties and action of the cardiotonic drug levosimendan

Effect of the stop-flow technique on cardiac retention of c-kit positive human cardiac stem cells after intracoronary infusion in a porcine model of chronic ischemic cardiomyopathy